Navigation Links
Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
Date:11/6/2008

CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that an oral presentation covering the interim results of a U.S. Phase II trial investigating intravenous REOLYSIN(R) in patients with bone and soft tissue sarcomas metastatic to the lung is being delivered today by Dr. Monica Mita of the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas at the Chemotherapy Foundation Symposium XXVI, which is being held in New York from November 4-8, 2008.

"REOLYSIN(R) is a very well tolerated treatment that is also showing promising results in patients with metastatic sarcoma," said Dr. Mita. "We are pleased with the results and honored to present the data at major meetings."

To date, 35 patients have been enrolled in the study, and 29 are evaluable. 21% (6/29) of the evaluable patients experienced stable disease (SD) for more than 16 weeks. The investigators concluded that the study has met its established objectives, and that enrolment will continue to the full 52 patients.

-------------------------------------------------------------------------

Tumour Type Cycles Best Response

-------------------------------------------------------------------------

Synovial sarcoma 17* SD

-------------------------------------------------------------------------

Ewing's sarcoma 9* SD

-------------------------------------------------------------------------

Malignant Fibrous Histiocytoma 7* SD, tumor resection

after cycle 4

-------------------------------------------------------------------------

Leiomyosarcoma 6 SD

-------------------------------------------
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
2. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
3. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
4. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
5. Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
6. Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
7. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
8. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
9. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
10. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
11. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 ... release of the HELM biomolecular representation standard software ... MIT licence. HELM (Hierarchical Editing Language ... range of biomolecules (e.g. proteins, nucleotides, antibody drug ... and sequence-based informatics methodologies impractical or unusable. HELM ...
(Date:6/18/2013)... , June 18, 2013 Mapi ... (APIs), generic and innovative intermediates, and finished dosage forms based ... has been granted a United States ... Europe for the oral treatment of ... is titled Intermediate Compounds and Processes for the Preparation ...
(Date:6/18/2013)... , June 18, 2013   Lexicon Pharmaceuticals, ... biopharmaceutical company focused on discovering breakthrough treatments for ... has joined the company as its vice ... Northcott brings extensive commercial experience to Lexicon, including ... variety of therapeutic areas. Mr. Northcott ...
(Date:6/18/2013)... June 18, 2013 New user friendly ... 200 prevent the dangers of misuse and ineffective ... knobs, analog pressure gauges, hot surfaces and complex door ... a new, modern autoclave, Revolutionary Science explains some important ... Older autoclave designs will recycle dirty water. ...
Breaking Biology Technology:The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools 2Mapi Pharma Granted United States Patent for Pain Relief Medication "Tapentadol" 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3How to Autoclave: Why the User Friendliness of the Saniclave 200 is So Important Today 2
... ) today reported results for the third quarter ended September,30, ... per share, for,the third quarter 2007, from a net loss ... 2006. Cash and short-term investments totaled,$13.9 million at September 30, ... quarter 2007 is due to a 21%,decrease in operating expenses ...
... Reports Results for the Nine Month Period Ended September ... ... results for the nine month period ended September 30, 2007,as follows: Revenues ... September 30, 2007. In the same period of 2006, Genmab,recognised DKK 105.6 million ...
... ANN ARBOR, Mich., Oct. 30 NanoBio(R) ... commercializing novel,products for the prevention and treatment ... Joyce Sutcliffe, Ph.D., as vice president of,research. ... in the discovery and design of,new antibiotics, ...
Cached Biology Technology:Pharmos Corporation Reports 2007 Third Quarter Results 2Pharmos Corporation Reports 2007 Third Quarter Results 3Pharmos Corporation Reports 2007 Third Quarter Results 4Pharmos Corporation Reports 2007 Third Quarter Results 5Genmab Announces Results for the First Nine Months of 2007 2Genmab Announces Results for the First Nine Months of 2007 3Genmab Announces Results for the First Nine Months of 2007 4Dr. Joyce Sutcliffe Joins the NanoBio Team as Vice President of Research 2
(Date:6/17/2013)... and a major cause is a deadly fungus thought ... shows they can also die from this pathogen, contrary ... that just spreads the disease. , When researchers raised ... found at least one strain of this pathogen, ... fungus, can be fatal to year-old juveniles. However, bullfrogs ...
(Date:6/16/2013)... programs for female sex workers in India reduce rates ... a University of Toronto study has found. ... mostly in the southern states of Andhra Pradesh, Karnataka, ... Prabhat Jha from U of T,s Dalla Lana School ... Global Health Research (CGHR), examined the impact of prevention ...
(Date:6/16/2013)... A "cold snap" 116 million years ago triggered a ... past as a result of global warming, according to ... international study involving experts from the universities of Newcastle, ... global cooling and a crash in the marine ecosystem ... quantifies for the first time the amplitude and duration ...
Breaking Biology News(10 mins):Bullfrogs may help spread deadly amphibian fungus, but also die from it 2HIV prevention among female sex workers in India reduces HIV and syphilis 2Global cooling as significant as global warming 2
... recently received two grants from the National Science ... on the Implications of Cutting-Edge Biotechnologies for Sustainability ... research on the use of on-line prediction markets ... The workshop will develop an EU-U.S. trans-disciplinary research ...
... Joseph, Michigan A new internet-based tool for designing ... and to optimize design by allowing rapid development of ... of Resource: Engineering & Technology for a Sustainable ... and Agricultural Engineering at the University of Missouri, introduces ...
... investigation an international body of earth scientists has formally agreed ... by 800,000 years, reports the Journal of Quaternary Science ... International Commission on Stratigraphy (ICS), the authority for geological science ... declaring when the Quaternary Period, which covers both the ice ...
Cached Biology News:Web-based innovation improves, eases agricultural terrace design 2End of an era: New ruling decides the boundaries of Earth's history 2
... peptide derived from the C-terminal region of ... D iris-expressed growth factor spinal cord-derived growth ... rat by one amino acid replacement. ... mouse and rat PDGF-D proteins. Reactivity: ...
Antibodies were affinity purified using epitopes specific to USP33 immobilized on solid support....
...
... 100% ,human IgG subclass 2 ... 100% ,human IgG subclass 4 ... 100% ,human IgG Fc ... IgG Fab ...
Biology Products: